John Lewis

*** ******** *****

Somerset, KY *2501-1848

606-***-**** or 606-***-****

ablcs1@r.postjobfree.com

Career Objective: To obtain a sales/management position

Education: BA Business-Finance, Eastern Kentucky University

Experience: Alcon Labs. 3/10-Present. Detailing ENTs,

Pediatricians and Family doctors on Ciprodex, Vigamox, Pataday

and Patanase. Since I have taken over the territory I have

increased market share for all products. I cover almost all

of Southern, Central and Eastern Kentucky. I do breakfast,

lunch and learns, dinner, dinner programs and speaker

programs.

ABBOTT LABS. Pain Consultant. 9/08-8/09.

Promoting Synthroid and Vicoden CR. Vicoden CR did not get FDA

approval and the sales force was eliminated. I gained

commitments from healthcare providers even though I didn't

have a sales aid or package insert. Proper use and potential

abuse were discussed and campaigns such as Not In My House and

Partnership for a Drug Free America were promoted.

OSCIENT PHARMACEUTICALS. Lipid-Cardiovascular Consultant.

04/07-5/08. Territory Manager promoting Antara and Factive.

The following are my accomplishments:

Grew Antara New Rx share from 2.97% to 6.18% 4Q 07

1st in District NRxs for Antara 4Q 07

4th in District Share Growth for Antara 4Q 07

2nd in District New Rxs for Antara 4Q 07

2nd in District NRx Volume for Antara 4Q 07

3rd in District NRx Share Growth for Factive 4Q 07

PROFESSIONAL DETAILING INC. from 10/01-12/06. I promoted

pharmaceuticals for ELI LILLY, ASTRAZENECA AND

GLAXOSMITHKLINE. For GSK I promoted Advair, Coreg, Paxil CR,

Avodart, Malarone and Requip from 01/05-12/06. I helped RE-

LAUNCH Paxil CR and Requip. For AstraZeneca I was a

Pharmaceutical Sales Specialist promoting Crestor and Nexium

from 2/04-12/04. Lastly, I was on the Eli Lilly contract

promoting Evista, Ceftin, Quixin, Welchol and Lotensin from

10/01-02/03. The following are my accomplishments:

1st in district Paxil CR market share growth, 4Q 05 (GSK)

2nd in district Advair market share growth, 2Q 06 (GSK)

3rd in district market share growth for Requip, Advair &

Avodart, 2Q 06 (GSK)

3rd in the nation for Requip, Advair & Avodart, 3Q 06 (GSK)

2nd in the region for Nexium market share growth, 2nd Q 04

(AZ)

64th out of 510 nationally for Evista (Eli Lilly)

30th nationally for Lotensin market growth, Oct. of 02 (Eli

Lilly)

Contact this candidate